From Zero to Informed
in Four Sessions.

The Reality of Being the Sponsor

In an early-stage biotech, it's easy to view a trial entirely through the lens of the science. But once you take on the sponsor role, that trial becomes a massive logistical exercise. This session sets the baseline for execution.

• The key players: Clarifying the specific responsibilities of the sponsor, investigator, site staff, ethics committees, regulators, and vendors. We'll also look at why the company funding the trial and the legal sponsor aren't always the same thing.
• How study types dictate operations: We'll cover the practical, on-the-ground differences of running Phase 1 in healthy volunteers versus patients, Phase 2 proof-of-concept studies, and investigator-initiated trials.
• The true timeline: From finalizing the protocol to dosing the first patient and hitting database lock. We'll break down exactly where the months go and why. (This is almost always the section where executives say, "I wish I knew this a year ago.")

The GCP Playbook: What You Must Do vs. Who Can Do It

This session is the turning point of the masterclass. Regulators outline exactly what a sponsor is responsible for, but they leave the how completely up to you. Understanding this distinction is the key to running a leaner trial.

• Translating the rules: We strip the jargon out of the guidelines to clarify what must happen, what you can outsource, and why you always retain ultimate accountability.
• Line-by-line obligations: We'll walk through a matrix covering your core duties, from safety reporting and data management to site management and quality. You'll see the rule, the most cost-effective ways to fulfill it, and the proof an auditor will demand.
• Deconstructing monitoring: You must monitor your sites, but nothing mandates using a traditional CRO. We'll look at how combining freelance CRAs, internal staff, and centralized data review satisfies the requirement while protecting your budget.
• Surviving an inspection: A quick, grounded look at what regulators actually care about when inspecting an early-stage sponsor. (Hint: it's usually not what leadership teams assume.)

Deconstructing the CRO (Operations, Pricing, and Alternatives)

To effectively manage a CRO, you have to understand how they are built. They are scaled for Big Pharma volume and processes, which is why early-stage biotechs often feel like they are getting the "B-team" and a flood of change orders. It's a structural mismatch in cultures.

• Staffing the study: What you are buying in a full-service contract, and the hard truth about why the experts at the bid defense inevitably hand your study over to someone else.
• Following the money: We take a hard look at the bid grid, FTE vs. unit pricing, pass-throughs, and change orders. You'll learn how to read a proposal and why the initial contract is never the final price.
• Knowing when to buy in: There are specific cases where outsourcing everything to one vendor is the smartest strategic move. We'll explore the options.
• Unbundling the trial: How to run your study without a large full-service CRO. We'll explore functional service providers, regional partners, hybrid vendor models, and building an internal team with freelance contractors — plus what infrastructure you need to actually pull it off.

Global Strategy, Trial Reality, and Your Final Blueprint

• The geography of clinical trials: A practical guide to where you can run the study. We cover a rapid-fire comparison of key global markets (from EU, USA, Latin America, to Australia and Moldova). For each, we look at the only metrics that matter to a sponsor: submission speed, major regulatory hurdles, and bottom-line cost.
• The operational reality of study types: We break down how different trial designs dictate your day-to-day. You'll learn the limits of relying on a Phase 1 unit, the logistical jump of multi-site Phase 2 studies, and the realities of investigator-initiated trials — focusing on how the final data will actually serve your corporate goals.
• The true cost of your protocol: This one is about protocol realism. You'll see how seemingly small scientific choices — like extra clinic visits, sample logistics, and strict inclusion criteria — directly translate into massive budget burn and schedule delays.
• Choosing your model: Your final blueprint. A framework that weighs your available funding, company stage, and internal headcount to select the optimal operational setup. We'll look at examples and highlight the classic pitfalls to avoid.